Clinical Trial Update: A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating amantadine for cognitive dysfunction in Long COVID/Post-Acute COVID-19 Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute COVID-19 Syndrome
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• amantadine (amantadine)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Status: WITHDRAWN